Try a new search

Format these results:

Searched for:

person:koides01

in-biosketch:yes

Total Results:

197


The integrated stress response promotes immune evasion through lipocalin 2

Bossowski, Jozef P; Pillai, Ray; Kilian, John; Wong Lau, Angela; Nakamura, Mari; Rashidfarrokhi, Ali; Hao, Yuan; Li, Ruxuan; Wu, Katherine; Hattori, Takamitsu; Glasser, Eliezra; Koide, Akiko; Wang, Lidong; Moreira, Andre L; Hajdu, Cristina; Rajalingam, Sahith; LeBoeuf, Sarah E; Le, Hortense; Lee, Seungeun; Oh, Jin Woo; Joe, Cheolyong; Kim, Hyemin; Ock, Chan-Young; Lee, Se-Hoon; Wang, Hao; Patel, Angana A H; Sayin, Volkan I; Tsirigos, Aristotelis; Wong, Kwok-Kin; Koralov, Sergei B; Pende, Mario; Sánchez-Rivera, Francisco J; Simeone, Diane M; Zervantonakis, Ioannis K; Koide, Shohei; Papagiannakopoulos, Thales
Cancer cells activate the integrated stress response (ISR) to adapt to stress and resist therapy1. ISR signals converge on activating transcription factor 4 (ATF4), which controls cell-intrinsic transcriptional programs that are involved in metabolic adaptation, survival and growth2,3. However, whether the ISR-ATF4 axis influences anti-tumour immune responses remains mostly unknown. Here we show that loss of ATF4 decreases tumour progression considerably in immunocompetent mice, but not in immunocompromised ones, by enhancing T cell-dependent anti-cancer immune responses. An unbiased genetic screen of ATF4-regulated genes identifies lipocalin 2 (LCN2) as the principal ATF4-dependent effector that impairs anti-tumour immunity by favouring infiltration with immunosuppressive interstitial macrophages. Furthermore, we find that LCN2 promotes T cell exclusion and immune evasion in preclinical mouse models, and correlates with decreased T cell infiltration in patients with lung and pancreatic adenocarcinomas. Anti-LCN2 antibodies promote robust anti-tumour T cell responses in mouse models of aggressive solid tumours. Our study shows that the ATF4-LCN2 axis has a cell-extrinsic role in suppressing anti-cancer immunity, and could pave the way for an immunotherapy approach that targets LCN2.
PMID: 41708864
ISSN: 1476-4687
CID: 6004852

Engineering antibody-drug conjugates targeting an adhesion GPCR, CD97

Hattori, Takamitsu; Wang, Michelle; Corrado, Alexis D; Gross, Suzanne; Fang, Michelle; Bang, Injin; Roy, Nainita; Berezniuk, Iryna; Donaldson, Hayley; Groff, Karenna; Ravn-Boess, Niklas; Koide, Akiko; Placantonakis, Dimitris G; Park, Christopher Y; Koide, Shohei
Adhesion G protein-coupled receptors (aGPCRs) are key cell-adhesion molecules involved in many cellular functions and contribute to human diseases, including cancer. aGPCRs are characterized by large extracellular regions that could serve as readily accessible antigens. However, the potential of aGPCRs as targets for biologic therapeutics has not been extensively explored. CD97, also known as ADGRE5, is an aGPCR that is upregulated in various cancer types, including acute myeloid leukemia (AML) and glioblastoma (GBM), and their respective cancer stem cells. Here, we developed antibody-drug conjugates (ADCs) targeting CD97 and assessed their efficacy against AML and GBM cells. We generated a panel of synthetic human antibodies targeting distinct epitopes of CD97, from which we identified an antibody that was efficiently internalized. This antibody binds to all isoforms of human CD97 but not to its close homolog, EMR2. Structure determination by single-particle cryo-electron microscopy revealed that this antibody targets the CD97 GPCR autoproteolysis-inducing (GAIN) domain, whose presence is conserved in aGPCRs, through an unconventional binding mode where it extensively utilizes the light chain framework for antigen recognition. Screening of conjugation methods and payloads resulted in a stable ADC that effectively killed AML and GBM cell lines, as well as patient-derived GBM stem cells, with minimal cytotoxicity against peripheral blood mononuclear cells from healthy donors. Our study demonstrates the therapeutic potential of targeting CD97, as well as the aGPCR GAIN domain in general, and uncovers a previously unrecognized surface that an antibody can utilize for antigen recognition.
PMCID:12519206
PMID: 41026810
ISSN: 1091-6490
CID: 5966232

Selective targeting of oncogenic hotspot mutations of the HER2 extracellular domain

Bang, Injin; Hattori, Takamitsu; Leloup, Nadia; Corrado, Alexis; Nyamaa, Atekana; Koide, Akiko; Geles, Ken; Buck, Elizabeth; Koide, Shohei
Oncogenic mutations in the extracellular domain (ECD) of cell-surface receptors could serve as tumor-specific antigens that are accessible to antibody therapeutics. Such mutations have been identified in receptor tyrosine kinases including HER2. However, it is challenging to selectively target a point mutant, while sparing the wild-type protein. Here we developed antibodies selective to HER2 S310F and S310Y, the two most common oncogenic mutations in the HER2 ECD, via combinatorial library screening and structure-guided design. Cryogenic-electron microscopy structures of the HER2 S310F homodimer and an antibody bound to HER2 S310F revealed that these antibodies recognize the mutations in a manner that mimics the dimerization arm of HER2 and thus inhibit HER2 dimerization. These antibodies as T cell engagers selectively killed a HER2 S310F-driven cancer cell line in vitro, and in vivo as a xenograft. These results validate HER2 ECD mutations as actionable therapeutic targets and offer promising candidates toward clinical development.
PMID: 39438724
ISSN: 1552-4469
CID: 5739862

Creating MHC-restricted neoantigens with covalent inhibitors that can be targeted by immune therapy

Hattori, Takamitsu; Maso, Lorenzo; Araki, Kiyomi Y; Koide, Akiko; Hayman, James; Akkapeddi, Padma; Bang, Injin; Neel, Benjamin G; Koide, Shohei
Intracellular oncoproteins can be inhibited with targeted therapy, but responses are not durable. Immune therapies can be curative, but most oncogene-driven tumors are unresponsive to these agents. Fragments of intracellular oncoproteins can act as neoantigens presented by the major histocompatibility complex (MHC) but recognizing minimal differences between oncoproteins and their normal counterparts is challenging. We have established a platform technology that exploits hapten-peptide conjugates generated by covalent inhibitors to create distinct neoantigens that selectively mark cancer cells. Using the FDA-approved covalent inhibitors sotorasib and osimertinib, we developed "HapImmuneTM" antibodies that bind to drug-peptide conjugate/MHC complexes but not to the free drugs. A HapImmuneTM-based bispecific T cell engager selectively and potently kills sotorasib-resistant lung cancer cells upon sotorasib treatment. Notably, it is effective against KRASG12C mutant cells with different HLA supertypes, HLA-A*02 and A*03/11, suggesting loosening of MHC restriction. Our strategy creates targetable neoantigens by design, unifying targeted and immune therapies.
PMID: 36250888
ISSN: 2159-8290
CID: 5360222

Selective and noncovalent targeting of RAS mutants for inhibition and degradation

Teng, Kai Wen; Tsai, Steven T; Hattori, Takamitsu; Fedele, Carmine; Koide, Akiko; Yang, Chao; Hou, Xuben; Zhang, Yingkai; Neel, Benjamin G; O'Bryan, John P; Koide, Shohei
Activating mutants of RAS are commonly found in human cancers, but to date selective targeting of RAS in the clinic has been limited to KRAS(G12C) through covalent inhibitors. Here, we report a monobody, termed 12VC1, that recognizes the active state of both KRAS(G12V) and KRAS(G12C) up to 400-times more tightly than wild-type KRAS. The crystal structures reveal that 12VC1 recognizes the mutations through a shallow pocket, and 12VC1 competes against RAS-effector interaction. When expressed intracellularly, 12VC1 potently inhibits ERK activation and the proliferation of RAS-driven cancer cell lines in vitro and in mouse xenograft models. 12VC1 fused to VHL selectively degrades the KRAS mutants and provides more extended suppression of mutant RAS activity than inhibition by 12VC1 alone. These results demonstrate the feasibility of selective targeting and degradation of KRAS mutants in the active state with noncovalent reagents and provide a starting point for designing noncovalent therapeutics against oncogenic RAS mutants.
PMCID:8113534
PMID: 33976200
ISSN: 2041-1723
CID: 4867382

Mechanism of disease and therapeutic rescue of Dok7 congenital myasthenia

Oury, Julien; Zhang, Wei; Leloup, Nadia; Koide, Akiko; Corrado, Alexis D; Ketavarapu, Gayatri; Hattori, Takamitsu; Koide, Shohei; Burden, Steven J
Congenital myasthenia (CM) is a devastating neuromuscular disease, and mutations in DOK7, an adaptor protein that is crucial for forming and maintaining neuromuscular synapses, are a major cause of CM1,2. The most common disease-causing mutation (DOK71124_1127 dup) truncates DOK7 and leads to the loss of two tyrosine residues that are phosphorylated and recruit CRK proteins, which are important for anchoring acetylcholine receptors at synapses. Here we describe a mouse model of this common form of CM (Dok7CM mice) and a mouse with point mutations in the two tyrosine residues (Dok72YF). We show that Dok7CM mice had severe deficits in neuromuscular synapse formation that caused neonatal lethality. Unexpectedly, these deficits were due to a severe deficiency in phosphorylation and activation of muscle-specific kinase (MUSK) rather than a deficiency in DOK7 tyrosine phosphorylation. We developed agonist antibodies against MUSK and show that these antibodies restored neuromuscular synapse formation and prevented neonatal lethality and late-onset disease in Dok7CM mice. These findings identify an unexpected cause for disease and a potential therapy for both DOK7 CM and other forms of CM caused by mutations in AGRIN, LRP4 or MUSK, and illustrate the potential of targeted therapy to rescue congenital lethality.
PMID: 34163073
ISSN: 1476-4687
CID: 4918552

The γδ IEL effector API5 masks genetic susceptibility to Paneth cell death

Matsuzawa-Ishimoto, Yu; Yao, Xiaomin; Koide, Akiko; Ueberheide, Beatrix M; Axelrad, Jordan E; Reis, Bernardo S; Parsa, Roham; Neil, Jessica A; Devlin, Joseph C; Rudensky, Eugene; Dewan, M Zahidunnabi; Cammer, Michael; Blumberg, Richard S; Ding, Yi; Ruggles, Kelly V; Mucida, Daniel; Koide, Shohei; Cadwell, Ken
Loss of Paneth cells and their antimicrobial granules compromises the intestinal epithelial barrier and is associated with Crohn's disease, a major type of inflammatory bowel disease1-7. Non-classical lymphoid cells, broadly referred to as intraepithelial lymphocytes (IELs), intercalate the intestinal epithelium8,9. This anatomical position has implicated them as first-line defenders in resistance to infections, but their role in inflammatory disease pathogenesis requires clarification. The identification of mediators that coordinate crosstalk between specific IEL and epithelial subsets could provide insight into intestinal barrier mechanisms in health and disease. Here we show that the subset of IELs that express γ and δ T cell receptor subunits (γδ IELs) promotes the viability of Paneth cells deficient in the Crohn's disease susceptibility gene ATG16L1. Using an ex vivo lymphocyte-epithelium co-culture system, we identified apoptosis inhibitor 5 (API5) as a Paneth cell-protective factor secreted by γδ IELs. In the Atg16l1-mutant mouse model, viral infection induced a loss of Paneth cells and enhanced susceptibility to intestinal injury by inhibiting the secretion of API5 from γδ IELs. Therapeutic administration of recombinant API5 protected Paneth cells in vivo in mice and ex vivo in human organoids with the ATG16L1 risk allele. Thus, we identify API5 as a protective γδ IEL effector that masks genetic susceptibility to Paneth cell death.
PMID: 36198790
ISSN: 1476-4687
CID: 5351622

Inhibition of RAS function through targeting an allosteric regulatory site

Spencer-Smith, Russell; Koide, Akiko; Zhou, Yong; Eguchi, Raphael R; Sha, Fern; Gajwani, Priyanka; Santana, Dianicha; Gupta, Ankit; Jacobs, Miranda; Herrero-Garcia, Erika; Cobbert, Jacqueline; Lavoie, Hugo; Smith, Matthew; Rajakulendran, Thanashan; Dowdell, Evan; Okur, Mustafa Nazir; Dementieva, Irina; Sicheri, Frank; Therrien, Marc; Hancock, John F; Ikura, Mitsuhiko; Koide, Shohei; O'Bryan, John P
RAS GTPases are important mediators of oncogenesis in humans. However, pharmacological inhibition of RAS has proved challenging. Here we describe a functionally critical region, located outside the effector lobe of RAS, that can be targeted for inhibition. We developed NS1, a synthetic binding protein (monobody) that bound with high affinity to both GTP- and GDP-bound states of H-RAS and K-RAS but not N-RAS. NS1 potently inhibited growth factor signaling and oncogenic H-RAS- and K-RAS-mediated signaling and transformation but did not block oncogenic N-RAS, BRAF or MEK1. NS1 bound the alpha4-beta6-alpha5 region of RAS, which disrupted RAS dimerization and nanoclustering and led to blocking of CRAF-BRAF heterodimerization and activation. These results establish the importance of the alpha4-beta6-alpha5 interface in RAS-mediated signaling and define a previously unrecognized site in RAS for inhibiting RAS function.
PMCID:5193369
PMID: 27820802
ISSN: 1552-4469
CID: 2304332

Promiscuous RNA binding by WDR5 remodels the KMT2A (MLL1) histone methyltransferase complex to an inactive state

Kainth, Amoldeep S; Sirjoosingh, Pallavi; Werner, Michael S; Gupta, Ankit; Koide, Akiko; Koide, Shohei; Ruthenburg, Alexander J
Chromatin-modifying complexes are critical in gene regulation, yet their proposed interactions with RNA remain poorly understood. Counter to prior models of specific recruitment, we find that WDR5, an essential subunit of the MLL1/KMT2A histone methyltransferase complex, binds RNA promiscuously. Using a stringent approach, we demonstrate that WDR5 directly engages a diverse pool of cellular RNAs, dictated primarily by RNA abundance rather than specific motifs. Equilibrium binding assays show that RNA length, rather than sequence, governs high affinity. WDR5 binds to RNA through multiple surfaces, some of which overlap with MLL1 complex subunit interfaces. Strikingly, we find that RNA binding disrupts the MLL1 complex by competitively displacing WDR5 from these critical protein-protein interactions, leading to a marked inhibition of MLL1 catalytic activity. Further experiments in human cell lines suggest that this disassembly mechanism may operate to homeostatically downregulate MLL1 complex activity, thereby integrating transcriptional activity with chromatin state.
PMID: 42673957
ISSN: 1097-4164
CID: 6071932

TagC-RED: An Infrared-Triggered Retro-Ene Reaction for Deep-Tissue Bioconjugation

Suh, Sang Mi; Ben-Zvi, Benjamin; Talbott, John M; Manoj, Niket; Nelson, Brock M; Hughes, Riley R; Haug, Graham C; Koide, Shohei; Paton, Robert S; Raj, Monika; Diao, Tianning
Bioconjugation reactions are indispensable for probing biomolecules in their native environments. Photoactivatable bioconjugation offers spatiotemporal control; however, current methods face significant limitations, including the requirement for noncanonical functional groups, cytotoxic heavy-metal catalysts, and high-energy UV or visible light (λ < 800 nm), which restrict tissue penetration and increase phototoxicity risks. In response, we introduce TagC-RED, a Retro-Ene type sigmatropic rearrangement of Diazonium compounds for Cysteine-specific bioconjugation activated by infrared light (λ > 1000 nm). TagC-RED is quantitative, rapid, and catalyst-free, with deep tissue penetration, enabling robust labeling intracellularly and in vivo. Mechanistic studies and DFT calculations show that TagC-RED activates through the formation of an electron donor-acceptor (EDA) complex that enables IR irradiation and undergoes a stepwise retro-ene reaction. TagC-RED holds significant potential as a platform for in vivo chemical biology and diagnostic innovation.
PMCID:13195677
PMID: 42108585
ISSN: 1520-5126
CID: 6037572